Skip to search formSkip to main contentSkip to account menu

Removab

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Prognostic impact of epithelial cell adhesion molecule in ovarian cancer patients
To the editor: Epithelial cell adhesion molecule (EpCAM) was originally discovered in 1979, then, subsequent studies identified… 
2014
2014
Catumaxomab (Removab) – Trifunctional Antibodies: Combining Direct Tumor Cell Killing with Therapeutic Vaccination
2011
2011
FLAME PROPAGATION OF DUST AND GAS-AIR MIXTURES IN A TUBE
The flame propagation of hybrid (nicotinic acid/methane-air) mixtures has been studied using the open-tube method. During the… 
2010
2010
Catumaxomab in the Treatment of Malignant Ascites: the Evidence of its Therapeutic Value
The trifunctional, bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) is a new therapeutic strategy for epithelial cancer… 
2009
2009
Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3): Results of a Phase 1/2 Study
Catumaxomab is a trifunctional monoclonal antibody consisting of a mouse immunoglobulin G2a part and a rat immunoglobulin G2b… 
2005
2005
[T-cells activated with a trifunctional bi-specific antibody in head and neck cancer].
BACKGROUND The trifunctional bi-specific antibody Removab bridges and activates CD3 positive T cells to EpCAM on carcinoma cells… 
2004
2004
Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study.
2504 Background: Malignant ascites is the abnormal accumulation of fluid within the peritoneal cavity due to the peritoneal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)